For example, inhibiting lipogenesis via suppressing the expression of ACCs can reduce hepatic steatosis, but it simultaneously results in hypertriglyceridemia due to the activation of SREBP-1c and increased VLDL secretion (40). This evidence concerns the gene SREBF1 and fatty liver disease.